Cardiff Oncology Inc(CRDF) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Current Price

$9.01

RSI

42.075

Beta:

1.83177

February 25, 2021
869.5K
-5.2M

28.817 %
25.571 %
-54.760 %
-13.931 %

$365,993
$244,632
$370,890
$-2,184,360
$-994,440
$312,812
49.610 %
-51.611 %
688.951 %
-54.475 %
-131.456 %

$-19,278,428
$-16,416,137
$-16,224,345
$-24,906,744
$-39,202,719
$-27,471,094
-14.847 %
-1.168 %
53.515 %
57.398 %
-29.926 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.